Figure 5
Figure 5. Pharmacokinetics of very prolonged Erwinia asparaginase use in relation to AAAs. Serum Erwinia asparaginase activity (A) and serum AAAs (B) against Erwinia asparaginase (Erwinia-AAAs) over time. Serum Erwinia asparaginase activity levels of patients without Erwinia-AAAs (C) and with Erwinia-AAAs (D) (mean ± SEM). Dashed lines in panels A, C, and D indicate Erwinia asparaginase activity level of 100 U/L. The dashed line in panel B indicates samples defined as positive for Erwinia-AAAs if the OD was >1.96 standard deviations above the negative control processed mean (using Westgard rules).20

Pharmacokinetics of very prolonged Erwinia asparaginase use in relation to AAAs. Serum Erwinia asparaginase activity (A) and serum AAAs (B) against Erwinia asparaginase (Erwinia-AAAs) over time. Serum Erwinia asparaginase activity levels of patients without Erwinia-AAAs (C) and with Erwinia-AAAs (D) (mean ± SEM). Dashed lines in panels A, C, and D indicate Erwinia asparaginase activity level of 100 U/L. The dashed line in panel B indicates samples defined as positive for Erwinia-AAAs if the OD was >1.96 standard deviations above the negative control processed mean (using Westgard rules).20 

Close Modal

or Create an Account

Close Modal
Close Modal